Just finally listened to webcast, and went back to look at a few things.

Revising my previous comment slightly.

Still hanging on as in leaving money on the table at what might be a giveaway.

But I just don't think this is necessarily a permanent loss.

Just went back to Bear's helpful post reminding us specifically what the top line vs. specified subgroup analyses etc. were. Here are some key points from that post: 

"Primary Outcome: Time to first occurrence of adjudication-confirmed narrowly defined MACE (single composite endpoint of CV death or non-fatal MI or stroke). 

Beyond just the primary outcome are pre-specified subgroup analyses for the primary endpoint in BETonMACE that include:

 – Rosuvastatin/Atorvastatin

 – < 30 days/> 30 days post-acute coronary syndrome

 – LDL/HDL/TG’s above and below median

 – HbA1c above and below median

 – eGFR >60 mL/min and < 60 mL/min

 • Also change in eGFR for all patients with eGFR <60 mL/min

 There are quite a number of secondary outcomes that get into the individual MACE components, clinical chemistry, kidney function and adverse events."

Clearly, it was either the Lipitor thing, OR perhaps MACE didn't quite meet significance or met significance but not at the specified percentage, or met it only with Rosuvastatin OR maybew it didn't meet at all but the Diabetes or Stroke or Dementia data was strong. (I say stroke because of the recent talk on anti-thrombotic properties).

I think they are trying to hint to us in every way that they got something.

Not just because they have to in this situation.

But because they did.

It still hurts that the primary was not met.

I am not sure just how much it hurts or if the pre-defined subgroup analyses will be sufficient.

But frankly, if I were more flush, I might buy more right now with the price likely tanking again.

JUST my opinion, AND just my prayer.

For those who need it medically, and for those who were heavily invested.